Alvesco inhalation spray (ciclesonide)
Alvesco is a steroid intended for inhalation to control persistent asthma in adolescents and adults (12 years or more). In mild to moderate asthma treatment with ciclesonide leads to the same improvement in lung function (FEV1 and PEF) as equivalent doses of beclomethasone, budesonide, and fluticasone. Clinical studies of the drug used for COPD have not been performed. Ciclesonide can be considered when oral candisiasis trouble the patient. There are no difference in the frequency of well known steroid related systemic adverse events in adolescents and adults. The preparation is developed for single daily dosing, but it has not been confirmed that this posology improve drug consumption or the control of symptoms. The price of 12 months treatment is not considerably different from other relevant alternatives. However, there may be some savings when high doses of steroids are needed.
It is IRF’s overall assessment that Alvesco is an equal alternative to existing steroid preparations for the treatment of mild to moderate asthma. Alvesco was marketed August 20th 2012. At the present it is subject to reimbursement.